Halle Moore, MD, discusses the results of the IBIS-II DCIS trial of anastrozole versus tamoxifen after 12 years of follow-up for postmenopausal patients with locally excised ductal carcinoma in situ.
Halle Moore, MD, an oncologist in the department of hematology and medical oncology at the Cleveland Clinic, discusses the results of the IBIS-II DCIS trial (NCT00072462) of anastrozole versus tamoxifen after 12 years of follow-up for postmenopausal patients with locally excised ductal carcinoma in situ (DCIS).
The original presentation of this trial did not show a difference between these 2 agents but demonstrated the noninferiority of anastrozole when compared with tamoxifen, according to Moore. There were no significant variances in the risk of recurrence of these patients in the updated analysis, with about a 1% difference. For invasive recurrence or more rarely death from breast cancer in these patients with noninvasive breast cancer, there were no changes in the outcomes for these 2 drugs. The main difference was for the toxicity profiles.
Moore says that this trial shows there are options for patients with DCIS. Patients with severe osteoporosis with concerns of muscular-skeletal symptoms may be prescribed tamoxifen as a risk-reducing agent. On the other hand, patients at risk for blood clots or uterine cancer may receive an aromatase inhibitor. Both are reasonable options to consider in this setting, she thinks.
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen